KR102719165B1 - 바소프레신 v1a 수용체 길항제로서 트리아졸로벤즈아제핀 - Google Patents

바소프레신 v1a 수용체 길항제로서 트리아졸로벤즈아제핀 Download PDF

Info

Publication number
KR102719165B1
KR102719165B1 KR1020207020172A KR20207020172A KR102719165B1 KR 102719165 B1 KR102719165 B1 KR 102719165B1 KR 1020207020172 A KR1020207020172 A KR 1020207020172A KR 20207020172 A KR20207020172 A KR 20207020172A KR 102719165 B1 KR102719165 B1 KR 102719165B1
Authority
KR
South Korea
Prior art keywords
triazolo
chloro
trans
dihydro
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207020172A
Other languages
English (en)
Korean (ko)
Other versions
KR20200100111A (ko
Inventor
페렌크 바스카
에바 보조
임레 바타
크리스티나 존딘 코르다스
크리스티나 부키스
Original Assignee
리히터 게데온 닐트.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리히터 게데온 닐트. filed Critical 리히터 게데온 닐트.
Publication of KR20200100111A publication Critical patent/KR20200100111A/ko
Application granted granted Critical
Publication of KR102719165B1 publication Critical patent/KR102719165B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08Oxygen atoms
    • C07D223/10Oxygen atoms attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020207020172A 2017-12-15 2018-12-14 바소프레신 v1a 수용체 길항제로서 트리아졸로벤즈아제핀 Active KR102719165B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1700521 2017-12-15
HU1700521A HU231206B1 (hu) 2017-12-15 2017-12-15 Triazolobenzazepinek
PCT/IB2018/060077 WO2019116324A1 (en) 2017-12-15 2018-12-14 Triazolobenzazepines as vasopressin v1a receptor antagonists

Publications (2)

Publication Number Publication Date
KR20200100111A KR20200100111A (ko) 2020-08-25
KR102719165B1 true KR102719165B1 (ko) 2024-10-17

Family

ID=89992589

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207020172A Active KR102719165B1 (ko) 2017-12-15 2018-12-14 바소프레신 v1a 수용체 길항제로서 트리아졸로벤즈아제핀

Country Status (23)

Country Link
US (1) US11298363B2 (https=)
EP (1) EP3724192B1 (https=)
JP (1) JP7428647B2 (https=)
KR (1) KR102719165B1 (https=)
CN (1) CN111479813B (https=)
AR (1) AR113933A1 (https=)
AU (1) AU2018385724B2 (https=)
BR (1) BR112020011880A2 (https=)
CA (1) CA3085562A1 (https=)
CL (1) CL2020001564A1 (https=)
CU (1) CU24630B1 (https=)
EA (1) EA202091344A1 (https=)
HU (1) HU231206B1 (https=)
IL (1) IL275084B2 (https=)
JO (1) JOP20200149B1 (https=)
MX (1) MX2020006204A (https=)
PE (1) PE20210671A1 (https=)
PH (1) PH12020500548A1 (https=)
SG (1) SG11202005299VA (https=)
TN (1) TN2020000083A1 (https=)
TW (1) TWI826406B (https=)
UA (1) UA129516C2 (https=)
WO (1) WO2019116324A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
WO2022018121A1 (en) * 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Cyclohexyl substituted triazoles as vasopressin receptor v1 a antagonists
TWI804119B (zh) * 2020-12-21 2023-06-01 大陸商上海濟煜醫藥科技有限公司 三氮唑類三并環衍生物及其製備方法和應用
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2023164710A1 (en) * 2022-02-28 2023-08-31 The Trustees Of Columbia University In The City Of New York Avpr1a blockade to reduce social isolation-induced anxiety in females
US12310974B1 (en) 2023-12-19 2025-05-27 Samuel Aballea Method of treating post-traumatic stress disorder with carpipramine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074291A1 (en) 2003-02-19 2004-09-02 Pfizer Limited Triazole compounds useful in therapy
JP2006517921A (ja) 2003-02-19 2006-08-03 ファイザー・インク 治療に有用なトリアゾール化合物
JP2007517857A (ja) 2004-01-13 2007-07-05 ファイザー・インク 治療に有用な化合物
WO2011131596A1 (en) 2010-04-21 2011-10-27 F. Hoffmann-La Roche Ag Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists
WO2014048945A1 (de) 2012-09-28 2014-04-03 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 5-aryl-triazolo-azepine

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382185B1 (en) 1989-02-10 1994-06-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
FR2679903B1 (fr) 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
EP1097920B1 (en) 1993-07-21 2004-09-22 Yamanouchi Pharmaceutical Co. Ltd. Intermediate for condensed benzazepine derivatives
ES2284741T3 (es) 1994-06-15 2007-11-16 Otsuka Pharmaceutical Company, Limited Derivados de benzoheterociclicos utilizados como moduladores de vasoprsinao de oxitocina.
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
SK16242002A3 (sk) 2000-05-19 2003-04-01 Merck Patent Gmbh Derivát triazolu a farmaceutický prostriedok, ktorý ho obsahuje
US7001898B2 (en) 2000-07-05 2006-02-21 Ortho-Mcneil Pharmaceutical, Inc. Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
US7056910B2 (en) 2000-11-28 2006-06-06 Astellas Pharma Inc. 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof
MXPA04003358A (es) 2001-10-12 2004-07-08 Serenix Pharmaceuticals Llc Antagonistas de vasopresina v1a de ?-lactamilo.
JP2005104838A (ja) 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
EA010132B1 (ru) 2003-12-22 2008-06-30 Пфайзер Инк. Производные триазола в качестве антагонистов вазопрессина
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
CA2578370A1 (en) 2004-08-25 2006-03-02 Pfizer Inc. Triazolobenzodiazepines and their use as vasopressin antagonists
CA2593044A1 (en) 2004-12-31 2006-07-13 Abbott Gmbh & Co. Kg Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
CA2602194A1 (en) 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
ES2434467T3 (es) 2005-05-13 2013-12-16 Lexicon Pharmaceuticals, Inc. Compuestos multicíclicos y métodos para su uso
CA2615726C (en) 2005-07-14 2014-05-27 Caterina Bissantz Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
KR100984893B1 (ko) 2005-07-21 2010-10-01 에프. 호프만-라 로슈 아게 V1a 수용체 길항제로서의인돌-3-일-카보닐-피페리딘-벤조이미다졸 유도체
EP2392571A3 (en) 2005-07-29 2012-03-14 F. Hoffmann-La Roche AG Indol-3-yl-carbonyl-piperidin and piperazin derivatives
DE102006051796A1 (de) * 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate
JP2010517966A (ja) 2007-02-01 2010-05-27 グラクソ グループ リミテッド 摂食障害の処置のための1−オキサ−3−アザスピロ(4.5)デカン−2−オンおよび1−オキサ−3,8−ジアザスピロ(4.5)デカン−2−オン誘導体
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
BRPI0922303B1 (pt) 2008-11-28 2019-11-12 Hoffmann La Roche arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
TW201103907A (en) 2009-03-20 2011-02-01 Lundbeck & Co As H Amide derivatives as neuropeptide Y5 receptor ligands
SG10201406839VA (en) 2009-10-26 2014-12-30 Otsuka Pharma Co Ltd Benzazepine compound
GB201004677D0 (en) 2010-03-19 2010-05-05 Vantia Ltd New salt
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
EP2569280B1 (en) 2010-05-11 2015-02-25 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
US20130237530A1 (en) * 2010-11-15 2013-09-12 Agenebio, Inc. Benzodiazepine derivatives, compositions and methods for treating cognitive impairment
CN105263910A (zh) 2013-02-18 2016-01-20 斯克利普斯研究所 具有治疗潜力的血管加压素受体调节剂
EP3230281B1 (en) 2014-12-09 2021-05-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
RU2017131562A (ru) 2015-02-27 2019-03-27 Версеон Корпорейшн Замещенные пиразольные соединения как ингибиторы сериновых протеаз
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
CN106349241B (zh) * 2015-07-15 2020-04-21 上海翰森生物医药科技有限公司 具有hsp90抑制活性的三唑衍生物及其制备方法和应用
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
AR108263A1 (es) 2016-05-03 2018-08-01 Bayer Pharma AG Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
EP3452472A1 (en) 2016-05-03 2019-03-13 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074291A1 (en) 2003-02-19 2004-09-02 Pfizer Limited Triazole compounds useful in therapy
JP2006517921A (ja) 2003-02-19 2006-08-03 ファイザー・インク 治療に有用なトリアゾール化合物
JP2007517857A (ja) 2004-01-13 2007-07-05 ファイザー・インク 治療に有用な化合物
WO2011131596A1 (en) 2010-04-21 2011-10-27 F. Hoffmann-La Roche Ag Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists
WO2014048945A1 (de) 2012-09-28 2014-04-03 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 5-aryl-triazolo-azepine
JP2015531362A (ja) 2012-09-28 2015-11-02 バイエル ファーマ アクチエンゲゼルシャフト Betタンパク質阻害性の5−アリールトリアゾロアゼピン

Also Published As

Publication number Publication date
CA3085562A1 (en) 2019-06-20
KR20200100111A (ko) 2020-08-25
UA129516C2 (uk) 2025-05-21
IL275084A (en) 2020-07-30
CU20200048A7 (es) 2021-03-11
EP3724192A1 (en) 2020-10-21
MX2020006204A (es) 2020-08-27
JP7428647B2 (ja) 2024-02-06
US11298363B2 (en) 2022-04-12
CU24630B1 (es) 2022-12-12
SG11202005299VA (en) 2020-07-29
EA202091344A1 (ru) 2020-09-09
JOP20200149B1 (ar) 2022-10-30
AU2018385724B2 (en) 2023-05-25
TWI826406B (zh) 2023-12-21
BR112020011880A2 (pt) 2020-11-24
AU2018385724A1 (en) 2020-07-09
WO2019116324A1 (en) 2019-06-20
TW201938170A (zh) 2019-10-01
JP2021506821A (ja) 2021-02-22
EP3724192B1 (en) 2022-08-03
TN2020000083A1 (en) 2022-01-06
CL2020001564A1 (es) 2020-11-06
JOP20200149A1 (ar) 2020-06-10
HUP1700521A2 (en) 2019-06-28
PH12020500548A1 (en) 2021-01-25
CN111479813B (zh) 2023-03-21
IL275084B2 (en) 2023-06-01
CN111479813A (zh) 2020-07-31
HU231206B1 (hu) 2021-10-28
PE20210671A1 (es) 2021-04-05
AR113933A1 (es) 2020-07-01
US20210260072A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
KR102719165B1 (ko) 바소프레신 v1a 수용체 길항제로서 트리아졸로벤즈아제핀
DK3344616T3 (en) SUBSTITUTED AMINOTRIAZOLES USED AS HUMAN CHITINASE INHIBITORS
CN102066360B (zh) 喹啉或异喹啉取代的p2x7拮抗剂
WO2011141848A1 (en) Morpholine compounds as mineralocorticoid receptor antagonists
TW201132642A (en) Diaza-spiro[5.5]undecanes
WO2001070689A1 (en) DIPHENYLALKYLAMINE DERIVATIVES USEFUL AS OPIOID δ RECEPTOR AGONISTS
JP2005289816A (ja) ベンズイミダゾール誘導体
JP2017535545A (ja) 疼痛に対する多様な活性を有するスピロ−イソキノリン−1,4’−ピペリジン化合物
Kono et al. Discovery of orally efficacious RORγt inverse agonists. Part 2: design, synthesis, and biological evaluation of novel tetrahydroisoquinoline derivatives
TW201938171A (zh) 作為血管升壓素V1a受體拮抗劑之三環化合物
CN120590392A (zh) 药理学活性的杂环取代的吡唑并[1,5-a]嘧啶衍生物
CN105793266B (zh) 螺-噁唑酮
JP4748162B2 (ja) N−ジヒドロキシアルキル置換2−オキソイミダゾール誘導体
KR20220042379A (ko) 키티나제 억제제로서 유용한 치환된 아미노 트리아졸
EA042383B1 (ru) Триазолобензазепины как антагонисты v1a рецепторов вазопрессина
OA19571A (en) Triazolobenzazepines as vasopressin V1a receptor antagonists.
JP6337092B2 (ja) 三環式トリアゾール系化合物
EA049144B1 (ru) ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ ЗАМЕЩЕННЫЕ ПО ГЕТЕРОЦИКЛИЧЕСКОМУ ФРАГМЕНТУ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА
HK1223922B (zh) 螺-恶唑酮

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200713

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211202

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240219

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241009

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241015

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241015

End annual number: 3

Start annual number: 1

PG1601 Publication of registration